Group Leader: András Dinnyés
The HCEMM-USZ StemCell Group focuses on the investigation of human induced pluripotent stem cell (hiPSC) derived microgia cells from Alzheimer’s disease (AD) patients.
As Europe is an aging society, the prevalence of neurodegenerative diseases, especially AD is increasing and based on WHO predictions, AD will be the second leading cause of death after cardiovascular diseases by 2040. Furthermore, there is no effective treatment against AD. As for research aspects, the currently used animal models to test AD are far from eligible, since cognitive functions not necessarily correlates with tau phosphorylation and amyloid beta (Aβ) accumulation. On the other hand, obtaining primary cells from diseased brain is almost impossible. Based on these facts, the development of a novel model to understand AD pathogenesis in a more detailed way is urgent.
It is well known that beside neurons microglia cells play pivotal role in the pathogenesis and in the progression of AD by shifted cytokine and chemokine production. The HCEMM-USZ StemCell Group has availability to hiPSC cells from familiar (f) and sporadic (s) AD patients with different genetic background. The team will differentiate hiPSCs towards resting microglia (M0) and shifting them towards proinflammatory (M1) and anti-inflammatory (M2) phenotype with different cytokines and chemokines. The phenotypic analysis of M0, M1 and M2 microglia from sAD, fAD and healthy control will be performed with different methods by using HCEMM core facilities.